Skip to Content

Edaravone Pregnancy and Breastfeeding Warnings

Edaravone is also known as: Radicava

Edaravone Pregnancy Warnings

Safety has not been established during pregnancy. US FDA pregnancy category: Not Assigned Comments: Based on animal data, this drug may cause fetal harm.

Animal studies have revealed evidence of adverse developmental effects (increased mortality, decreased growth, delayed sexual development, altered behavior) at clinically relevant doses; most of these effects occurred at doses that were also associated with maternal toxicity. Although IV administration of this drug (3, 20, or 200 mg/kg) prior to and throughout mating in male and female animals and continuing in females to gestation day 7 had no effect on fertility, disruption of the estrus cycle and mating behavior were observed at the highest dose tested. No effects on reproductive function were observed at the lower doses, which are up to 3 times the recommended human dose on a body surface area basis. There are no controlled data in human pregnancy. US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

See references

Edaravone Breastfeeding Warnings

In animals administered this drug from gestation day 17 throughout lactation, adverse effects were observed including maternal toxicity, increased stillbirths, and delayed physical development (vaginal opening) and mortality in offspring.

Safety has not been established; benefit should outweigh risk. Excreted into human milk: Unknown Excreted into animal milk: Yes Comments: The effects in the nursing infant and on milk production are unknown.

See references

References for pregnancy information

  1. "Product Information. Radicava (edaravone)." MT Pharma America, Jersey City, NJ.

References for breastfeeding information

  1. "Product Information. Radicava (edaravone)." MT Pharma America, Jersey City, NJ.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.